24.7.2017 21:53 | Nasdaq OMX
Announcing the First U.S. Federally Regulated Exchange and Clearing House for Digital Currency Derivatives
NEW YORK, July 24, 2017 (GLOBE NEWSWIRE) -- LedgerX, the New York-based institutional trading and clearing platform for digital currencies, receives approval to operate the first U.S. federally-regulated exchange and clearing house for derivatives contracts settling in digital currencies.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/eafba6f5-a1ce-47da-81a0-0aaacfe7caef
See Related Release: The U.S. Commodity Futures Trading Commission (CFTC) grants LedgerX LLC a Derivatives Clearing Organization license (DCO) to clear and physically settle digital currency-based financial instruments.
LedgerX will be the first federally supervised options venue for bitcoin
Participants in the LedgerX venue will be able to obtain and hedge bitcoin and other digital currencies using exchange-traded and centrally-cleared options contracts. Initially, LedgerX anticipates listing one to six-month options contracts for bitcoin (BTC). Other digital currency contracts such as Ethereum (ETH) options, are expected to follow.
Regulated by the CFTC, an independent agency of the U.S. Federal Government, LedgerX will provide the surveillance and transparency institutional investors require. Eligible participants in the LedgerX venue will include registered broker dealers, banks, futures commission merchants, qualified commodity pool entities and qualified high net worth investors.
"A U.S. federally-regulated venue for derivative contracts settling in digital currencies opens the market to a much larger customer base," states Paul L. Chou, CEO, LedgerX. "We are seeing strong demand from institutions that previously could not participate in the bitcoin market due to compliance restrictions against unregulated venues," added Chou. "In particular, there is a desire for fund managers to hold financial instruments that are not correlated with the broader equity market, and digital currencies meet that need," concludes Chou.
"These are exciting times to have a new digital asset class emerge," comments Mark Wetjen, who sits on the board of directors for LedgerX's parent company, Ledger Holdings. "I hope that the effort LedgerX put forward in the U.S. can set the stage for a global approach to this new digital asset class," adds Wetjen.
"LedgerX's registration is a historic milestone for derivatives and for digital currencies," said Gary DeWaal of Katten Muchin Rosenman LLP, which assisted LedgerX during its CFTC application process. "To me, it is equivalent to the launch of currency futures back in 1972 that heralded the beginning of exchange-traded and cleared derivatives based on financial products," concludes DeWaal.
The CFTC granted LedgerX a Swap Execution Facility (SEF) registration on July 6, 2017. LedgerX is a limited liability company registered in Delaware with its primary place of business in New York, New York, U.S.A. www.LedgerX.com
Media Contact: Marie Giangrande +1.203-536-1334 Media@LedgerX.com
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
MatchBack Systems21.8.2017 22:01 | pressemeddelelse
ZIM Adds MatchBack Systems Analytics Services in Italy
Promethean, Inc.18.8.2017 18:40 | pressemeddelelse
Promethean Opens New Global Headquarters in Seattle
Hminers18.8.2017 11:01 | pressemeddelelse
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs
Nasdaq17.8.2017 18:51 | pressemeddelelse
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market
Tetraphase Pharmaceuticals17.8.2017 14:31 | pressemeddelelse
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
RedHill Biopharma Ltd.17.8.2017 13:01 | pressemeddelelse
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum